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The search for a rapid-acting antidepressant has been a subject of intense research interest for
several decades. The article by Lucas and colleagues in this issue of Neuron provides compelling
evidence from preclinical animal models that drugs acting at the serotonin 5-HT4 receptor could
finally achieve this goal. However, caution is warranted, as results from animal studies are not
always predictive of therapeutic actions in humans.A rapid-acting antidepressant has
been the holy grail of drug development
for mood disorders for many years, as
the action of typical antidepressants
requires weeks or even months for
a beneficial response. Moreover, the
efficacy of currently available antide-
pressants is relatively poor, often re-
quiring patients to try several different
agents over the course of many months
or even years, and still only about 65%
experience a successful treatment re-
sponse. These are critical issues for
the treatment of mood disorders that
afflict approximately 17% of the popu-
lation, resulting in an enormous eco-
nomic burden, poor quality of life, per-
sonal suffering, and suicide.
These concerns highlight the poten-
tial significance of the study by Lucas
and colleagues (Lucas et al., 2007)
demonstrating both rapid and effica-
cious actions of 5-HT4 receptor ago-
nists in preclinical, cellular, and behav-
ioral models of depression. If this work
translates to the development of rapid-
acting, clinically effective antidepres-
sant agents, the treatment of these
debilitating mood disorders would un-
dergo a sea change. However, clinical
trials are needed to test this possibility
and to assess potential side effects of
these agents.
The selective 5-HT reuptake inhibi-
tors (SSRIs) are the most widely pre-
scribed class ofantidepressants. These
agents increase synaptic levels of 5-HT
relatively quickly (hours or days), but
there is a delay in therapeutic response
(weeks or months) due to the likely
requirement for adaptations at both
pre- and postsynaptic sites (Blier and
DeMontigny, 1994; Duman et al., 1997;Berton and Nestler, 2006). At the pre-
synaptic level, desensitization of inhibi-
tory 5-HT1A autoreceptors must occur
to allow for continued firing and release
of 5-HT. With typical SSRI antidepres-
sants, this requires several weeks of
drug treatment. The first clue that 5-
HT4 receptor agonists might be rapid
acting came from earlier studies from
this group, demonstrating that these
agents increase the firing of 5-HT neu-
rons and that this effect is maximal after
only 3 days of agonist exposure (Lucas
et al., 2005). The current study confirms
this finding, and the results suggest that
the actions of 5-HT4 agonists include
a rapid desensitization of 5-HT1A auto-
receptors (Table 1). One question is how
this rapid occurs. The stimulation of
5-HT neuronal firing (which would lead
to higher synaptic levels of 5-HT) could
underlie a more rapid desensitization.
At the postsynaptic level, 5-HT4 re-
ceptor agonist administration also
leads to a rapid and robust response.
Increased postsynaptic receptor func-
tion (measured by the activity of 5-
HT1A receptors on CA3 pyramidal cells
in the hippocampus) is observed after 3
days of agonist administration com-
pared to several weeks reported for
SSRIs, and the magnitude is twice
that observed with chronic SSRI treat-
ment (Blier and DeMontigny, 1994;
Haddjeri et al., 1998) (Table 1). These
effects are blocked by depletion of 5-
HT, further showing the requirement
for 5-HT neuronal activation by the
5-HT4 agonist for an antidepressant-
like response. Molecular and cellular
markers of antidepressant action were
also examined, including phosphoryla-
tion of the cAMP response elementNeuron 55, Sepbinding protein (CREB), the active form
of this transcription factor, and neuro-
genesis in the dentate gyrus granule
cell layer in the adult hippocampus
(Nakagawa et al., 2002; Berton and
Nestler, 2006). Treatment with the
5-HT4 agonist causes a rapid increase
in phospho-CREB, again after only 3
days compared to 2–3 weeks for
SSRIs, and a greater response than
SSRIs alone (Table 1) (Tiraboschi et al.,
2004). Moreover, agonist treatment
rapidly increases neurogenesis in the
hippocampus, though this effect is not
superior to that observed after SSRI
antidepressants. While electroconvul-
sive seizure rapidly increases hippo-
campal neurogenesis, this is the first
demonstration that a chemical 5-HT
agent can also produce such an effect.
Most importantly, the functional sig-
nificance of these molecular and cellu-
lar studies is examined in additional
behavioral tests that provide better
models for mood disorders and antide-
pressant actions. While forced swim is
a useful, high-throughput, and reliable
test, classical antidepressants, includ-
ing SSRIs, produce a response after 1
or 2 days that is not consistent with
the therapeutic time course for these
agents (Duman et al., 1997; Berton
and Nestler, 2006).Thismakes it impos-
sible to determine whether a novel
agent has a more rapid onset of action.
To address this issue, as well as to ex-
amine behaviors with better construct
validity, the olfactory bulbectomy and
chronic mild stress models were exam-
ined. Both of these models require ad-
ministration of SSRIs for 2–3 weeks
before a response is observed, consis-
tent with the therapeutic time course.tember 6, 2007 ª2007 Elsevier Inc. 679
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Response/Action SSRI 5-HT4 Agonist
5-HT Neurons in the Dorsal Raphe Nucleus
Firing rate: acute (1d) drug inhibition stimulation
repeated drug basal rate (by 14 d) stimulation (max, 3 d) + sustained (21 d)
5-HT1A autoreceptor desensitization delayed (14 d) rapid (3 d)
Hippocampus: Antidepressant Responses
5-HT response, CA3 pyramidal cell delayed (14 d) rapid (3 d; 5-HT4 > SSRI)
Neurogenesis, dentate gyrus delayed (14 d) rapid (3 d; 5-HT4 = SSRI)
Phospho-CREB (hippocampal homogenate) delayed (4 d) rapid (3 d; 5-HT4 > SSRI)
Behavior: Antidepressant Response
Olfactory bulbectomy delayed (14 d) rapid (3 d) + sustained (14 d)
Chronic mild stress delayed (14 d) rapid (3 d) + sustained (24 d)
Forced swim test 1 d 1 dIn addition, chronic mild stress is con-
sidered one of the best animal models
that capture core symptoms of depres-
sion, including anhedonia, or the inabil-
ity toexperiencepleasure (measured by
consumption of a sweetened solution)
(Berton and Nestler, 2006). In both of
these models, 5-HT4 receptor agonist
administration produces a significant
reversalofdepressive-likebehaviors af-
ter 3 days, compared to 2 weeks for an
SSRI, providing strong support for the
potential rapid actions of these agents
(Table 1).
These exciting findings raise several
mechanistic and treatment-related
questions. The more rapid response
to the 5-HT4 receptor agonist is most
likely a result of parallel rapid and
sustained activation of 5-HT neuronal
firing, a possibility supported by the
electrophysiological studies of both
pre- and postsynaptic sites. Increased
5-HT neuronal firing could also underlie
the more efficacious effects of 5-HT4
agonists relative to SSRIs, since the ef-
fect of reuptake inhibition is dependent
on basal rates of 5-HT cell firing. How-
ever, it is also likely that the 5-HT4 re-
ceptor agonists have effects that are
independent of 5-HT neuronal firing.
This possibility is supported by the abil-
ity of these agents to directly activate
the cAMP/CREB-regulated signaling
pathway (Duman et al., 1997), while
other subtypes inhibit (e.g., 5-HT1A) or
are not directly coupled to this path-
way. Direct actions of 5-HT4 agonists680 Neuron 55, September 6, 2007 ª200at postsynaptic sites could also under-
lie the more rapid response to these
agents. Additionally, direct application
of a 5-HT4 agonist produces effects
on CA3 pyramidal neurons that are
opposite to systemic administration of
SSRIs or agonists, yet the responses to
5-HT4 agonists in other hippocampal
cell types could differ significantly. This
is particularly relevant to the regulation
of neurogenesis, which is reported to
involve both postsynaptic 5-HT1A recep-
tors and the cAMP-CREB cascade, and
will require further studies to elucidate.
The ability of 5-HT4 receptors to
stimulate 5-HT neuronal firing appears
to involve activation of receptors lo-
cated on neurons in the prefrontal cor-
tex (Lucas et al., 2005). Although the
identity of the cells that express 5-
HT4 receptors and their connections
with 5-HT neurons in the dorsal raphe
nucleus is not yet known, it is possible
that these cells project to other brain
regions that could contribute to the
antidepressant actions of 5-HT4 ago-
nists. Another notable aspect of this
study is that the actions of 5-HT4 re-
ceptors on neuronal firing and behav-
ior are sustained for several weeks.
This is surprising, as most receptors
desensitize and/or internalize upon
continued activation. The sustained
activation and lack of desensitization
are most likely related to the partial ag-
onist characteristics of the 5-HT4 ago-
nist used for these studies (Eglen et al.,
1995; Briejer et al., 2001), a possibility7 Elsevier Inc.that requires further analysis and
testing. This is a critical point, as sus-
tained activity of future compounds
could require similar partial agonist
properties.
Although much work remains to be
done, the side effects of 5-HT4 recep-
tor agonists could be fewer or different
relative to SSRIs, which would influ-
ence the quality of life and treatment
compliance of patients taking antide-
pressant drugs. Most notably, libido
is decreased in many SSRI-treated
patients, and it is possible that 5-HT4
agonists may not cause similar effects,
although this will require further testing.
Expression of 5-HT4 receptors in the
prefrontal cortex and hippocampus is
associated with increased learning,
memory, and cognition, another poten-
tial beneficial effect of 5-HT4 agonists
(Lamirault and Simon, 2001). However,
5-HT4 receptors are also expressed
in peripheral tissues, including the
gastrointestinal system and heart, and
could lead to additional side effects
(Hegde and Eglen, 1996). 5-HT4 ago-
nists have been used for the treatment
of gastrointestinal motility problems,
and depending on existing conditions,
this could be a benefit or potential
problematic side effect. Moreover, 5-
HT4 agonists are associated with atrial
arrhythmias, another potential problem
that must be closely examined.
In summary, the paper by Lucas
and colleagues provides an extensive
and convincing data set in support of
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agonists are rapid and efficacious anti-
depressant agents. However, these
agents will require extensive testing in
clinical trials for confirmation, due to
limitations inherent in rodent models
of depression and antidepressant re-
sponse and because of potential side
effects. It seems likely that these new
results presented in this report will
stimulate efforts to develop safe 5-
HT4 agonists that enter the brain and
that can be used to further test this
hypothesis in preclinical and ultimately
clinical trials that could lead to a much
needed novel, rapid, and improved
class of antidepressants.There’s More tha
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In two manuscripts published in
(Iwasato et al.), investigators hav
ephrinB3/EphA4-dependent mot
The diversity of signaling molecules
has long fascinated scientists and sug-
gested the possibility that particular
proteins might be required for specific
cellular events. However, examples of
signal transduction proteins acting
only during particular cellular events
have been few and far between. Now,
three papers provide a beautiful in vivo
example of a specific function for a
particular signaling molecule.Together,
the three manuscripts are striking for
the extent that they each describe
a similar set of results but use indepen-
dent approaches to do so: one group
began by identifying a spontaneous
mouse mutant (Iwasato et al., 2007),
a second used a yeast two-hybrid
screen (Wegmeyer et al., 2007), and
a third used a screen for protein-
protein interactions (Beg et al., 2007).REFERENCES
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While each paper offers its own strong
evidence for the role of a-chimaerin in
mediatingephrinB3/EphA4-dependent
motor circuit formation, together these
manuscripts provide a compelling and
unusually comprehensive picture of an
essential role for a particular GAP.
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chimaerin, is required in vivo for
a-chimaerins and two b-chimaerins
made as alternatively spliced products
of two genes. a2- and b2-chimaerin
also contain SH2 domains that enable
them to bind phosphorylated tyrosine
residues. The a-chimaerin GAPs are
expressed in brain and linked to axon
guidance (Diaz et al., 2002), sema-
phorin signaling (Brown et al., 2004),
dendritic spine development (Buttery
et al., 2006), and the NMDAR (Van de
Ven et al., 2005). These properties
made chimaerin an interesting candi-
date for regulating axonal growth in
the nervous system.
Work from a number of laboratories
has identified a specific role of eph-
rinB3/EphA4 forward signaling in the
formation of the motor circuit between
neurons in layer 5 of motor cortex and
the principle motor neurons in the
ptember 6, 2007 ª2007 Elsevier Inc. 681
